Anifrolumab

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Anifrolumab
   1. Pharmacist Assessment Report
   2. Anifrolumab: Known uses and market status in Canada
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Anifrolumab: Known uses and market status in Canada

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Anifrolumab, so there is currently no new predicted indication. The drug’s recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	1
Evidence level	Not applicable
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
systemic lupus erythematosus	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Canada Market Information

Licence	Product	Dosage form	Status
02522845	SAPHNELO		Valid

Safety Considerations

• Drug Interactions: The interaction query completed and returned one pharmacology entry rather than a drug-drug interaction: anifrolumab’s target is the interferon α/β receptor 1 (IFNAR1), where it acts as an antibody inhibitor. No clinically graded interactions were reported.

Please refer to the package insert for warnings and contraindications.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---